Recombinant Cynomolgus Monkey CD7 His-tag Protein, CF

When Recombinant Human SECTM1 Fc Chimera (Catalog # 7559-ST) is immobilized at 0.5 μg/mL, Recombinant Cynomolgus Monkey CD7 His-tag (Catalog #10214-CD) binds with an ED50 of 8-40 ng/mL.

2 μg/lane of Recombinant Cynomolgus Monkey CD7 His-tag (Catalog # 10214-CD)was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 37-44 kDa and 30-40 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey CD7 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human SECTM1 Fc Chimera (Catalog # 7559-ST) is immobilized at 0.5 μg/mL (100 μL/well), the concentration of Recombinant Cynomolgus Monkey CD7 that produces 50% of the optimal binding response 8-40 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey CD7 protein
  Ala26-Pro180, with C-terminal 6-His tag
• Accession #: XP_005585387.1
• N-terminal Sequence: Ala26
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 17 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 37-44 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey CD7 His-tag Protein, CF

• CD7 antigen (p41)
• CD7 antigen
• CD7 molecule
• CD7
• GP40T-cell surface antigen Leu-9
• LEU-9
• T-cell antigen CD7
• T-cell leukemia antigen
• Tp40
• TP41
• TP41p41 protein

Background

CD7, also known as Leu-9, is an approximately 40 kDa glycosylated and palmitoylated transmembrane protein in the immunoglobulin superfamily (1). Mature human CD7 consists of a 155 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment, and a 39 aa cytoplasmic domain (2). Within the ECD, human CD7 shares 43% and 41% aa sequence identity with mouse and rat CD7, respectively. CD7 is expressed on T cells (2, 3), NK cells (4), myeloid progenitor cells (5), and CD19⁺ B progenitor cells (6). Among CD8⁺ T cells, the CD7-bright population preferentially contains naïve and memory cells, while more weak expressors are primarily effector cells (7). CD7 associates in cis with CD3 and CD45 and in trans with SECTM1 (8, 9). Ligation of CD7 with antibodies or SECTM1 co‑stimulates the activation and proliferation of CD4⁺ and CD8⁺ T cells (10, 11) and NK cells (4, 9). It also enhances integrin-mediated adhesion of these cells to Fibronectin, ICAM-1, and VCAM-1 (3, 12). CD7 additionally mediates the Galectin-1 induced apoptosis of T cells (13) and facilitates the fusion of HIV-1 with target cells (14).

1. Sutherland, D.R. et al. (1984) J. Immunol. 133:327.
2. Aruffo, A. and B. Seed (1987) EMBO J. 6:3313.
3. Shimizu, Y. et al. (1992) J. Exp. Med. 175:577.
4. Rabinowich, H. et al. (1994) J. Immunol. 152:517.
5. Chabannon, C. et al. (1992) J. Immunol. 149:2110.
6. Grumayer, E.R. et al. (1991) Blood 77:64.
7. Aandahl, E.M. et al. (2003) J. Immunol. 170:2349.
8. Lazarovits, A.I. et al. (1994) J. Immunol. 153:3956.
9. Lyman, S.D. et al. (2000) J. Biol. Chem. 275:3431.
10. Wang, T. et al. (2012) J. Leukoc. Biol. 91:449.
11. Carrera, A.C. et al. (1988) J. Immunol. 141:1919.
12. Rabinowich, H. et al. (1994) J. Immunol. 153:3504.
13. Pace, K.E. et al. (2000) J. Immunol. 165:2331.
14. Sato, A.I. et al. (1994) J. Immunol. 152:5142.

Bioinformatics

• Uniprot:
  • XP_005585387.1()